Economic evaluation in implementation initiatives to improve HIV prevention, screening and treatment: a systematic review
Year: 2026
Type: preprint
Study design: Systematic Review
Abstract: Background The global response to HIV has achieved major advances, while the uptake of proven prevention, screening, and treatment technologies remains uneven, particularly in resource-limited settings. Implementation initiatives are essential to bridge this gap, but their economic implications are less systematically understood. Methods We conducted a systematic review to synthesize evidence on the implementation costs and economic evaluations of global initiatives designed to improve uptake of HIV-related technologies. We systematically searched MEDLINE, Embase, LILACS, PsycINFO, EconLit, and Web of Science for peer-reviewed studies published between 1981 and December 2024. We included studies that reported economic evaluations of implementation strategies aiming to enhance the uptake of HIV prevention, screening, or treatment technologies in low-, middle-, and high-income countries. We excluded studies based on hypothetical scenarios, technology-only evaluations, or non-HIV interventions. We extracted data on study characteristics, implementation strategies, outcomes, and costs using the ERIC and RE-AIM frameworks. We standardised costs to 2024 USD and synthesised economic findings narratively. We assessed study quality using the Drummond checklist. Results We screened 4,387 records and included 25 eligible studies. The interventions focused on prevention (n = 6), treatment (n = 5), screening (n = 12), or combined aims (n = 2). The most frequent implementation strategies involved engaging patients and communities, modifying infrastructure, and training providers. Implementation costs ranged from $2 to $11,979 per person reached, with lower averages in low- and middle-income countries ($108; range $3–660) than in high- and upper-middle-income settings ($1,694; range $2–11,979). We identified 16 studies that conducted full economic evaluations. Prevention and screening initiatives more frequently reported cost-effective or cost-saving results, while treatment studies showed greater variability, partly due to methodological and contextual differences. Conclusions Implementation costs and cost-effectiveness outcomes varied widely across settings and intervention types. Our findings highlight the need to standardise cost classification, reporting, and analytic methods to strengthen the integration of economic evidence within implementation science. We discussed how to improve methodological consistency to enhance comparability and policy relevance, supporting efficient and equitable progress toward global HIV targets. Registration: Protocol published on PROSPERO international database (CRD42024565223).
Source: Research Square
Institution: University of Bristol
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7162017008
